#Gilead Sciences

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.

The new single-tablet antiretroviral regimen includes the integrase inhibitor bictegravir and is the smallest such tablet on the market.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

This association held true even when researchers controlled for changing rates of viral suppression of HIV in 2012 to 2016 records.

Mark S. King offers his take on USCA and provides exclusive video from the event.

The iconic AIDS activist sounded off in a STAT interview—and shared how he’s spending his declining years.

If most folks are getting their PrEP for free, then who cares what Gilead charges?

As the current number of Americans on PrEP hits an estimated 180,000, scant numbers of teenagers have ever taken Truvada as HIV prevention.

This association held true even when researchers controlled for changing rates of viral suppression of HIV in 2012 to 2016 records.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

Three “high-profile advocates” share candid tales as part of Gilead’s video series to prevent HIV and STIs.

Among other issues: Out-of-pocket costs are increasingly passed on to consumers.

Gilead Sciences, the maker of Truvada as PrEP, launched the campaign to raise awareness of the HIV prevention method.

The “Healthysexual” campaign features young Black and Latino men, plus cisgender and transgender women. [VIDEO]

The Cleveland Leather Annual Weekend (CLAW) provides HIV education and awareness.